{"resourceType": "Group", "meta": {"versionId": "3", "lastUpdated": "2024-08-24T09:27:31.484Z", "profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/cohort-definition"]}, "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Brian S. Alper"}}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact", "valueRelatedArtifact": {"type": "cite-as", "citation": "CohortDefinition: T1DM or T2DM [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 270503. Revised 2024-08-24. Available at: https://fevir.net/resources/Group/270503. Computable resource at: https://fevir.net/resources/Group/270503."}}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-title", "valueString": "CohortDefinition: T1DM or T2DM"}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-url", "valueUri": "https://fevir.net/resources/Group/270503"}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-publisher", "valueString": "Computable Publishing LLC"}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-copyright", "valueMarkdown": "https://creativecommons.org/licenses/by-nc-sa/4.0/"}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-contact", "valueContactDetail": {"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/combination-method", "valueCode": "any-of"}], "id": "270503", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "https://fevir.net", "value": "270503", "assigner": {"display": "Computable Publishing LLC"}}], "characteristic": [{"code": {"coding": [{"system": "http://snomed.info/sct", "code": "64572001", "display": "Disease (disorder)"}]}, "valueCodeableConcept": {"coding": [{"system": "http://snomed.info/sct", "code": "46635009", "display": "Diabetes mellitus type 1 (disorder)"}]}, "exclude": false, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "T1DM"}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-method", "valueCodeableConcept": {"text": "based on the World Health Organization (WHO) diagnostic criteria, and have been on the following daily insulin therapy for at least 1 year\n.. i. multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or\n.. ii. continuous subcutaneous insulin infusion (CSII)"}}]}, {"code": {"coding": [{"system": "http://snomed.info/sct", "code": "64572001", "display": "Disease (disorder)"}]}, "valueCodeableConcept": {"coding": [{"system": "http://snomed.info/sct", "code": "44054006", "display": "Diabetes mellitus type 2 (disorder)"}]}, "exclude": false, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "T2DM"}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-method", "valueCodeableConcept": {"text": "based on the WHO diagnostic criteria, and have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n.. i. insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n.. ii. OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine"}}]}], "description": "diagnosis of either:\n. a. T1DM based on the World Health Organization (WHO) diagnostic criteria, and have been on the following daily insulin therapy for at least 1 year\n.. i. multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or\n.. ii. continuous subcutaneous insulin infusion (CSII) Or\n. b. T2DM based on the WHO diagnostic criteria, and have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n.. i. insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n.. ii. OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine", "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No data.]</div>"}, "membership": "definitional", "modifierExtension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-status", "valueCode": "active"}], "type": "animal"}